{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:14:38Z","timestamp":1790864078529,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jaip.2024.04.033","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T23:16:43Z","timestamp":1714087003000},"page":"2074-2083.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5209","authenticated-orcid":false,"given":"Arnaud","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Emerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Shavit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Kurdyukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Menzies-Gow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.04.033_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.04.033_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.04.033_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.04.033_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.04.033_bib5","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1007\/s12325-022-02340-w","article-title":"A\u00a0renewed charter: key principles to improve patient care in severe asthma","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaip.2024.04.033_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0151-2019","article-title":"Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety","volume":"29","author":"Price","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2024.04.033_bib7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.04.033_bib8","first-page":"1","article-title":"Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice","volume":"9","author":"Price","year":"2016","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.04.033_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.04.033_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201143","article-title":"Association between blood eosinophil count and risk of readmission for patients with asthma: historical cohort study","volume":"13","author":"Kerkhof","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2024.04.033_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2147\/JAA.S306416","article-title":"Persistence of eosinophilic asthma endotype and clinical outcomes: a real-world observational study","volume":"14","author":"Tran","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.04.033_bib12","article-title":"Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma","volume":"7","author":"Lee","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.jaip.2024.04.033_bib13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/JAA.S305513","article-title":"Health-related quality of life and productivity among US patients with severe asthma","volume":"14","author":"Soong","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.04.033_bib14","unstructured":"Fasenra (benralizumab) [package insert]. Wilmington, DE: Astrazeneca Pharmaceuticals;\u00a02021."},{"key":"10.1016\/j.jaip.2024.04.033_bib15","unstructured":"Nucala (mepolizumab) [package insert]. Philadelphia, PA: GlaxoSmithKline;\u00a02021."},{"key":"10.1016\/j.jaip.2024.04.033_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2024.04.033_bib17","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.04.033_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2024.04.033_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01217-2022","article-title":"Living without eosinophils: evidence from mouse and man","volume":"61","author":"Jackson","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.04.033_bib20","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2024.04.033_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","article-title":"Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab","volume":"43","author":"Jackson","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2024.04.033_bib22","first-page":"807","article-title":"Eosinophils and human cancer","volume":"12","author":"Samoszuk","year":"1997","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.jaip.2024.04.033_bib23","doi-asserted-by":"crossref","first-page":"P805","DOI":"10.1016\/j.mayocp.2022.01.037","article-title":"In reply\u2014are eosinophils needed for normal health?","volume":"97","author":"Wechsler","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2024.04.033_bib24","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1038\/s41467-020-19297-5","article-title":"Eosinophils improve cardiac function after myocardial infarction","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaip.2024.04.033_bib25","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.04.033_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.04.033_bib27","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.04.033_bib28","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.04.033_bib29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.04.033_bib30","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.04.033_bib31","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.04.033_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.04.033_bib33","article-title":"Standard-of-care asthma controller regimen reduction with benralizumab treatment: ANDHI in practice study","volume":"58","author":"Louis","year":"2021","journal-title":"Eur Respir Soc"},{"key":"10.1016\/j.jaip.2024.04.033_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/JAA.S227170","article-title":"Two-year integrated efficacy and safety analysis of benralizumab in severe asthma","volume":"12","author":"FitzGerald","year":"2019","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.04.033_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/02770903.2019.1705333","article-title":"Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma","volume":"58","author":"Bourdin","year":"2021","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2024.04.033_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/npjpcrm.2014.9","article-title":"Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey","volume":"24","author":"Price","year":"2014","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.jaip.2024.04.033_bib39","article-title":"Efficacy and safety on benralizumab compared with mepolizumab in the treatment of eosinophilic granulomatosis with polyangiitis in patients receiving standard of care therapy: phase 3 MANDARA study","volume":"75","author":"Wechsler","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2024.04.033_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.04.033_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2023.2169574","article-title":"Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis","volume":"34","author":"Signorovitch","year":"2023","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.jaip.2024.04.033_bib42","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824004185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824004185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:12:40Z","timestamp":1778523160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824004185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2213219824004185"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.04.033","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}